Regulation & law · 30/12/2005

National Institutes of Health to Consider Exclusive Patent License for Fusion Proteins Comprising Circularly Permuted Ligands

The National Institutes of Health is issuing a notice under 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) regarding the potential grant of an exclusive patent license to practice certain inventions, including those described in United States Patent No. 4,892,827 and U.S. Patent No. 5,635,599, related to fusion proteins comprising circularly permuted ligands.